Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III Study of Risk Directed Therapy for Infants With Acute Lymphoblastic Leukemia (ALL): Randomization of Highest Risk Infants to Intensive Chemotherapy +/- FLT3 Inhibition (CEP-701, Lestaurtinib; IND 76431; NSC 617807)

Trial Profile

A Phase III Study of Risk Directed Therapy for Infants With Acute Lymphoblastic Leukemia (ALL): Randomization of Highest Risk Infants to Intensive Chemotherapy +/- FLT3 Inhibition (CEP-701, Lestaurtinib; IND 76431; NSC 617807)

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 07 Sep 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lestaurtinib (Primary) ; Asparaginase; Asparaginase; Asparaginase; Cyclophosphamide; Cytarabine; Cytarabine; Daunorubicin; Dexamethasone; Dexamethasone; Etoposide; Filgrastim; Filgrastim; Folinic acid; Hydrocortisone; Mercaptopurine; Methotrexate; Methotrexate; Methotrexate; Methylprednisolone; Pegaspargase; Prednisone; Vincristine
  • Indications Acute biphenotypic leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 09 Aug 2023 Planned End Date changed from 20 Jul 2023 to 28 Jun 2024.
    • 17 Aug 2022 Planned End Date changed from 1 Sep 2018 to 20 Jul 2023.
    • 12 Mar 2020 Status changed to no longer recruiting.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top